CN115279340A - 利用粉末鼻内肾上腺素的治疗 - Google Patents

利用粉末鼻内肾上腺素的治疗 Download PDF

Info

Publication number
CN115279340A
CN115279340A CN202180020993.7A CN202180020993A CN115279340A CN 115279340 A CN115279340 A CN 115279340A CN 202180020993 A CN202180020993 A CN 202180020993A CN 115279340 A CN115279340 A CN 115279340A
Authority
CN
China
Prior art keywords
epinephrine
particles
pharmaceutical composition
type
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020993.7A
Other languages
English (en)
Chinese (zh)
Inventor
加利亚·铁姆辛-克雷兹
帕维尔·卡兹丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nasus Pharma Ltd
Original Assignee
Nasus Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasus Pharma Ltd filed Critical Nasus Pharma Ltd
Publication of CN115279340A publication Critical patent/CN115279340A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180020993.7A 2020-03-16 2021-03-16 利用粉末鼻内肾上腺素的治疗 Pending CN115279340A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US62/989,913 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
US17/135,528 2020-12-28
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
CN115279340A true CN115279340A (zh) 2022-11-01

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020993.7A Pending CN115279340A (zh) 2020-03-16 2021-03-16 利用粉末鼻内肾上腺素的治疗

Country Status (13)

Country Link
US (2) US11400045B2 (https=)
EP (1) EP4121005A1 (https=)
JP (1) JP2023517532A (https=)
KR (1) KR20220154709A (https=)
CN (1) CN115279340A (https=)
AR (1) AR121593A1 (https=)
AU (1) AU2021239084A1 (https=)
BR (1) BR112022018440A2 (https=)
CA (1) CA3175130A1 (https=)
IL (1) IL296268A (https=)
MX (1) MX2022011464A (https=)
TW (1) TW202200119A (https=)
WO (1) WO2021186437A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20250048076A (ko) * 2022-08-11 2025-04-07 드 모투 코르디스 피티와이 엘티디 흡입형 에피네프린 제형
TW202502309A (zh) * 2023-05-31 2025-01-16 瑞典商奥瑞克索股份公司 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166219A (zh) * 2010-05-25 2011-08-31 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
CN110505873A (zh) * 2018-02-06 2019-11-26 爱奇司治疗公司 鼻内肾上腺素制剂及治疗疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
MX2016002705A (es) 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166219A (zh) * 2010-05-25 2011-08-31 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2019038756A1 (en) * 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
CN110505873A (zh) * 2018-02-06 2019-11-26 爱奇司治疗公司 鼻内肾上腺素制剂及治疗疾病的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
国家药典委员会: "《中华人民共和国药典 2015年版 四部》", 31 July 2015, 中国医药科技出版社, pages: 9 - 10 *
姚静: "《药用辅料应用指南》", 31 August 2011, 中国医药科技出版社, pages: 122 - 124 *
程刚: "《生物药剂学 第5版》", 31 December 2019, 中国医药科技出版社, pages: 79 - 81 *

Also Published As

Publication number Publication date
CA3175130A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
TW202200119A (zh) 2022-01-01
WO2021186437A1 (en) 2021-09-23
KR20220154709A (ko) 2022-11-22
BR112022018440A2 (pt) 2022-11-01
MX2022011464A (es) 2022-11-14
US20210283050A1 (en) 2021-09-16
US11400045B2 (en) 2022-08-02
IL296268A (en) 2022-11-01
US20230105615A1 (en) 2023-04-06
AR121593A1 (es) 2022-06-22
JP2023517532A (ja) 2023-04-26
AU2021239084A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
CN115279340A (zh) 利用粉末鼻内肾上腺素的治疗
CN110996912A (zh) 用于鼻内递送的干粉组合物
AU2021200503B2 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
KR20030038541A (ko) 안정한 약물 전달용 금속 이온-지질 분말 약제학적 조성물및 그것의 사용 방법
EP2229148B1 (en) Process for preparing a particulate and crystalline drug substance
CN105101955A (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
CN118045069A (zh) 利用三流体喷嘴制备可吸入复合颗粒的方法
US20250387327A1 (en) Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US20140377365A1 (en) Sustained-release formulation of rotigotine
KR20050105490A (ko) 경폐 투여용 서방성 제제학적 조성물
Sallam Recent advances in the formulation development of inhalational dosage forms
BR112020023812A2 (pt) sal de cisteamina inovador para a preparação de partículas altamente respiráveis
CN107847482A (zh) 喷雾器用组合物
KR19990021931A (ko) 미세구형 전분의 항편두통 조성물
TWI597072B (zh) 包覆脂肪酸的β－致效劑之結晶微粒
CN121648088A (zh) 一种缓释的西维来司他或其盐的药物组合物及其制备方法
EA042652B1 (ru) Способ получения микрочастиц цистеамина гиалуроната
HK1218867B (zh) 活性剂的呼吸递送

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20221101

RJ01 Rejection of invention patent application after publication